RBMX and T-cell non-Hodgkin lymphoma: In hepatocellular carcinoma (HCC) and T-cell lymphoma, elevated RBMX expression enhances tumor progression and chemoresistance by stabilizing oncogenic long non-coding RNAs (lncRNAs), such as BLACAT1, or modulating RNA metabolism (75, 76).